oculenz-letters-shifted
Ocutrx Continues to Modernize the Medical Telehealth Industry with Fifth Patent for In-home Visual Field Test Monitoring and Alerting
May 04, 2021 09:40 ET | Ocutrx Technologies, Inc
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Ocutrx Technologies, Inc. an augmented/extended reality and surgical device manufacturing company focused on transforming healthcare technology,...
logo color s and clearside.jpg
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
May 04, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
May 03, 2021 16:08 ET | Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients ...
logo color s and clearside.jpg
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
May 03, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Sandoz
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
May 03, 2021 01:15 ET | Novartis Pharma AG
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts...
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
May 01, 2021 15:26 ET | Adverum Biotechnologies, Inc.
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose -- ...
NOVARTIS logo.jpg
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
May 01, 2021 07:05 ET | Novartis Pharma AG
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
April 27, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
TIP_link_300x300.jpg
Medical Devices Market Growth Sturdy at 6.1% CAGR to Outstrip $767,684.9 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com
April 26, 2021 12:30 ET | The Insight Partners
Pune, India., April 26, 2021 (GLOBE NEWSWIRE) -- Medical Devices Market: Key InsightsAccording to our new research study on “Medical Devices Market to 2027 – Global Analysis and Forecast – by...
logo_ProQR-150x150.png
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
April 23, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...